Human CellExp CD273 / B7-DC / PD-L2, human recombinant protein
PDL2, PD-L2, Butyrophilin B7-DC, CD273, PDCD1 ligand 2, PDCD1L2, PDCD1LG2
|Calculated MW||This protein is fused with polyhistidine tag at the C-terminus, has a calculated MW of 23.4 kDa. The predicted N-terminus is Leu 20. DTT-reduced Protein migrates as 35-48 kDa due to glycosylation.|
|Other Names||PDL2, PD-L2, Butyrophilin B7-DC, CD273, PDCD1 ligand 2, PDCD1L2, PDCD1LG2|
|Results||Measured by its binding ability in a functional ELISA. Immobilized rh B7-DC / PD-L2 / CD273 at 1 µg/mL (100 µl/well) can bind rhPDCD-1 with a linear range of 15 - 500 ng/ml.|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.|
|Storage||-20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH7.4. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Programmed cell death 1 ligand 2 (PD-L2 or PDCD1 ligand 2) is also known as Butyrophilin B7-DC, CD antigen CD273, which belongs to the immunoglobulin superfamily or BTN/MOG family. The expression of PD-L2 is up-regulated by IFNG/IFN-gamma stimulation in monocytes and induced on dendritic cells grown from peripheral blood mononuclear cells with CSF2 and IL-4. PD-L2 Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. PD-L2 interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.
Tseng S.-Y.,et al.J. Exp. Med. 193:839-846(2001).
Latchman Y.,et al.Nat. Immunol. 2:261-268(2001).
He X.-H.,et al.Acta Biochim. Biophys. Sin. 36:284-289(2004).
Humphray S.J.,et al.Nature 429:369-374(2004).
Zhang Z.,et al.Protein Sci. 13:2819-2824(2004).
If you have any additional inquiries please email technical services at email@example.com.